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Abstract
The aim of the study was to evaluate the need for active surveillance of antibiotic resistance in ambulatory infections. We measured
the prevalence of antibiotic resistance in urinary tract infections (UTIs) (n = 1018) and skin infections (n = 213) diagnosed in outpatients
between September 2008 and February 2009 in the Canton of Bern, Switzerland. Samples were stratiﬁed into ‘solicited’ (diagnostic
work-up for study purpose only) and ‘routine’ (diagnostic work-up as part of standard care). Susceptibility patterns were compared for
463 Escherichia coli isolates from UTIs (231 solicited; 232 routine) and 87 Staphylococcus aureus isolates from skin infections (35 solicited;
52 routine). Overall, E. coli showed higher susceptibility to ampicillin, amoxicillin–clavulanic acid and norﬂoxacin in solicited than in
routine samples. Among 15–45-year-old patients, susceptibility rates were comparable between solicited and routine samples for all
antibiotics except for amoxicillin–clavulanic acid. However, among patients >45 years old, isolates from routine samples showed lower
susceptibility to all b-lactams tested and quinolones than those from solicited samples. Extended-spectrum b-lactamase (ESBL)-producing
E. coli isolates were rare (solicited, 0.4%; routine, 1.7%; p 0.4). Susceptibility patterns of S. aureus were comparable between solicited
and routine samples. Therefore, in the outpatient setting, susceptibility rates for E. coli isolates differ by indication for urinary culture
and age. Surveillance based on samples taken during standard care may underestimate susceptibility rates for uncomplicated infections,
especially among the elderly. Reports of resistance data should include age stratiﬁcation.
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Introduction
Antibiotic resistance is increasing worldwide in developed
and developing countries [1]. Multidrug resistance in impor-
tant human pathogens is no longer restricted to high-risk
settings such as acute-care hospitals, but is now spreading in
the population at large [2]. Community-acquired methicillin-
resistant Staphylococcus aureus (MRSA) and extended spec-
trum b-lactamase (ESBL)-producing Escherichia coli are timely
examples of multidrug-resistant organisms causing commu-
nity-acquired infections [3]. Increasing resistance trends
introduce uncertainty about the correct choice of empirical
antibiotic treatment if information about the local resistance
epidemiology is lacking. This applies to the outpatient setting,
in which microbiological diagnosis in individual patients is not
recommended in standard care for common non-invasive
infections.
Enormous effort and progress have been made in the
establishment of large-scale resistance surveillance systems
around the globe [4]. There are now several databases avail-
able, many of which also provide resistance information for
the community setting. For economic reasons, such surveil-
lance programmes usually rely on passive collection of rou-
tine microbiological data, and some programmes are based
mainly on data from invasive isolates. Therefore, the resis-
tance information represents a selection of clinical situations,
such as severe infections and infections associated with high-
risk populations, and it may overestimate the resistance
prevalence of mild community-acquired infections, such as
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those of the upper respiratory tract, the lower urinary tract,
and the skin. These infections account for the majority of
prescribed antibiotics, and standard care does not require
microbiological work-up. Changes of empirical treatment
habits to broader regimens based on erroneous interpreta-
tion of surveillance data will introduce an unnecessary selec-
tion pressure and promote further resistance spread. An
illustrative example is provided by uncomplicated lower
urinary tract infections. Concerns about the rapid increase in
resistance to trimethoprim–sulphamethoxazole in E. coli has
started a vicious circle of increased use of quinolones fol-
lowed by raising quinolone resistance rates and the emer-
gence of ESBL-producing clones [5,6].
In this study, we present the resistance rates observed in
an active surveillance study conducted in ambulatory-care
patients presenting with acute uncomplicated urinary tract
infections (UTIs) or purulent skin infections. We compare
the resistance results of samples that would not have been
sent for analysis outside this study (solicited samples) with
those of routine samples.
Patients and Methods
Study population and deﬁnitions
This study fulﬁlled the ethical requirements of the Canton of
Bern. In August 2008, all general practitioners and dermatol-
ogists practising in the Canton of Bern, Switzerland, were
asked by the Department of Public Health to participate in
this prevalence study. Patients were recruited between 1
September 2008 and 28 February 2009. Consecutive patients
>15 years of age were included in the study if they fulﬁlled
the following criteria: (i) residing in the Canton of Bern; and
(ii) ﬁrst visit with a purulent wound infection or with a new
episode of a UTI, deﬁned as the presence of typical symp-
toms and a positive dipstick test result. Patients with wound
infections were recruited only once. Patients with UTIs
could be recruited twice, if the time interval between the
current and the last episode was longer than 30 days. Physi-
cians ﬁlled in a short questionnaire for each patient about
the clinical diagnosis, living conditions (at home vs. long-term
care), antibiotic consumption during the last 3 months, and
history of colonization with a multiresistant microorganism.
Physicians stated for each patient whether microbiological
diagnosis would have been performed independently of this
study. Physician residence was categorized into rural or non-
rural, according to the deﬁnition of the Swiss Federal Ofﬁce
of Statistics (http://www.bfs.admin.ch). Microbiological diag-
nosis included a wound swab for skin infection and a mid-
stream urine sample for UTI. All microbiological analyses
were performed at the Institute for Infectious Diseases,
University of Bern. Wound swabs were placed in Amies
transport medium without charcoal (Venturi Transystem;
Copan, Brescia, Italy). Urine samples were transported in
containers preﬁlled with boric acid preservative (Becton
Dickinson, Franklin Lakes, NJ, USA). Susceptibility testing
was performed with the Kirby–Bauer disk diffusion test, and
the results were interpreted according to CLSI (formerly
NCCLS) standards [7]. Testing of E. coli isolates for suscepti-
bility to nitrofurantoin and fosfomycin was introduced in
January 2009. All wound swabs were screened for MRSA,
with a biplate consisting of mannitol salt agar 4% (Oxoid,
Hampshire, UK) and oxacillin screen agar containing 6 lg of
oxacillin/mL (BioMe´rieux, Croponne, France). Cefuroxime-
resistant Enterobacteriaceae were screened for ESBL accord-
ing to the CLSI ESBL recommendations for disk diffusion,
including ceftriaxone, ceftazidime, and aztreonam. The sec-
ond screening criterion was visible inhibition by clavulanic
acid (amoxicillin–clavulanic acid placed between aztreonam
and ceftazidime on screening plates). The presence of ESBL
was conﬁrmed by the double-disk test [8]. Signiﬁcant bacteri-
uria was deﬁned as a concentration of ‡1000 CFU/mL for
E. coli and Staphylococcus saprophyticus, and a concentration of
‡10 000 CFU/mL for all other microorganisms, according to
the European guidelines [9].
Statistical analysis
Samples that would have been collected by physicians for
diagnostic purposes independently of the study were desig-
nated as ‘routine samples’, and all others as ‘solicited sam-
ples’. In E. coli, ‘dual resistance’ was deﬁned as resistance to
norﬂoxacin and trimethoprim–sulphamethoxazole, and ‘multi-
resistance’ was deﬁned as resistance to three or more of
norﬂoxacin, trimethoprim–sulphamethoxazole, amoxicillin–
clavulanic acid, and cefuroxime axetil.
Data were analysed with Epi info Version 3.4.3 (CDC,
Atlanta, GA, USA). Proportions were compared by use of
the chi-square test or Fisher’s exact test as appropriate.
Results
Antimicrobial resistance prevalence in urinary tract isolates
In total, 1018 urine samples were provided by a total of
124 physicians, who account for 13% of all practising physi-
cians in the ambulatory setting in the Canton of Berne
(http://www.fmh.ch). Each physician recruited a median
number of three patients. Of the 1018 urine samples, about
half (n = 525, 51.6%) represented ‘routine samples’ and 428
(42.0%) ‘solicited samples’ (information was missing for 65
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samples (6.4%); Fig. 1). Assuming that the participating phy-
sicians cared for 13% of the population of the Canton of
Bern (n = 969 299; http://www.be.ch), the annual incidence
rate of UTIs amounted to 1.6 episodes per 100 population
per year.
Table 1 shows socio-demographic, clinical and microbio-
logical characteristics for solicited and routine samples.
Solicited samples were more often from patients of younger
age, of female gender, residing in urban regions, and living at
home. Also, patients with solicited samples less often had a
history of antibiotic treatment.
About two-thirds (68.5%) of urine samples showed signiﬁ-
cant bacteriuria. Signiﬁcant bacteriuria with a single micro-
organism was more frequent in routine samples (87.9%) than
in solicited samples (81.3%, p <0.001). E. coli was the most
prevalent microorganism, and the proportion of E. coli was
higher among solicited samples. The distribution of other
microorganisms was comparable between routine and solic-
ited samples.
Antimicrobial susceptibility rates for E. coli are shown in
Fig. 1. Susceptibility rates were signiﬁcantly higher among the
solicited samples for ampicillin, amoxicillin–clavulanic acid,
and norﬂoxacin. Also, E. coli isolates from solicited samples
were less often multidrug-resistant. After stratiﬁcation for
age, susceptibility rates differed between solicited and
routine samples for ampicillin, amoxicillin–clavulanic acid,
cefuroxime and norﬂoxacin in patients >45 years old, but
differed only for amoxicillin–clavulanic acid in patients
between the ages of 15 and 45 years (Table 1). Susceptibility
rates for norﬂoxacin were signiﬁcantly higher among younger
patients (95.7%) than among older patients (82.9%,
p <0.001), whereas susceptibility rates for other antibiotics
were comparable between the two age groups (Table 1).
Prior antimicrobial treatment was associated with signiﬁ-
cantly higher resistance rates for all antibiotics tested except
for fosfomycin, for which no resistance was observed
(Table 2).
ESBLs were detected in ﬁve (1.1%) E. coli isolates or in
0.8% of all culture-positive urine samples (0.4% in solicited
and 1.7% in routine samples, p 0.4). ESBL carriers were not
known previously in any of these patients. All were females,
and their age ranged between 16 and 80 years. Four of the
ﬁve ESBL carriers had a history of recurrent UTI and anti-
microbial exposure during the past 3 months. Two of the
ﬁve ESBL isolates were multiresistant (to gentamicin, tri-
methoprim–sulphamethoxazole, and norﬂoxacin).
Antimicrobial resistance prevalence in skin and soft tissue
infections
A total of 213 samples from skin and soft tissue infections
were provided by a total of 72 physicians. More than half of
these samples (n = 113, 53.1%) were routine samples, and
84 (39.4%) were collected explicitly for the study (informa-
tion was missing for 16 samples (7.5%)). Table 3 shows
socio-demographic and clinical data, and microbiological
results. Solicited samples differed from routine samples by
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FIG. 1. Susceptibility rates (%) of Escherichia coli urinary tract isolates in routine vs. solicited samples. The numbers of isolates tested were 231
for solicited samples and 232 for routine samples, except for fosfomycin (31 for each) and nitrofurantoin (40 for solicited samples and 48 for
routine samples). Signiﬁcant differences between solicited and routine samples are indicated by an asterisk (*p <0.05).
CMI Kronenberg et al. Antibiotic resistance in outpatients 1847
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 1845–1851
younger age, lower rate of chronic ulcers and lower rate of
antimicrobial treatment during the preceding 3 months.
In 64.5% of all samples, at least one established human
pathogen was detected. Mixed ﬂora was reported in 27.9%
of cultures, and in 7.6% there was no bacterial growth. The
microbial spectra were similar for routine and solicited sam-
ples, with S. aureus being the most prevalent pathogen iso-
lated. Antibiotic susceptibility rates for S. aureus are shown
in Fig. 2. Susceptibility rates were comparable for all anti-
biotics tested in both solicited and routine samples.
MRSA isolates were rare, with a prevalence of 2.1% (two
of 94, one in a routine sample and one in a solicited samples).
One of the two patients had been known to carry MRSA, and
he had a history of polytrauma with prolonged hospitalization
and multiple antibiotic treatments. The MRSA isolate from
TABLE 1. Socio-demographic, clini-
cal and microbiological characteris-
tics of patients with urinary tract
infectionsa
Solicited
samples,
n = 428
Routine
samples,
n = 525 p
Demographic and clinical characteristics
Age (years), mean (SD) 48.3 (22.3) 55.7 (23.0) <0.001
Female gender, n (%) 358 (83.6) 409 (77.9) 0.006
Rural, n (%) 128 (29.2) 212 (40.4) 0.001
Antimicrobial treatment during the
last 3 months, n (%)
48 (11.2) 228 (43.4) <0.001
Bladder catheter, n (%) 21 (4.9) 36 (6.9) >0.05
ESBL carriage known, n (%) 2 (0.5) 8 (1.5) >0.05
Long-term care, n (%) 11 (2.6) 38 (7.2) 0.002
Bacteriology
Bacteriuria, n (%)b 305 (71.3) 348 (66.3) >0.05
Single microorganism 248 (81.3) 323 (87.9) <0.001
Escherichia coli 231 (75.7) 232 (66.7) 0.01
Klebsiella spp. 13 (4.3) 22 (6.3) >0.05
Proteus mirabilis 10 (3.3) 14 (4.0) >0.05
Other Enterobacteriaceae 16 (5.2) 17 (4.9) >0.05
Pseudomonas aeruginosa 2 (0.7) 6 (1.7) >0.05
Enterococcus spp. 61 (20.0) 52 (14.9) >0.05
Staphylococcus aureus 3 (1.0) 5 (1.4) >0.05
Staphylococcus saprophyticus 10 (3.3) 17 (4.9) >0.05
Streptococcus agalactiae 6 (2.0) 6 (1.7) >0.05
Other 5 (1.6) 17 (4.9) 0.04
Susceptibility rates for Escherichia coli, n (%)
Age 15–45 years
Ampicillin 107 (67.3) 78 (57.7) >0.05
Amoxicillin–clavulanic acid 107 (85) 78 (69.2) 0.016
Cefuroxime axetil 107 (76.6) 78 (73.1) >0.05
Fosfomycin 16 (100.0) 11 (100.0) >0.05
Nitrofurantoin 21 (95.2) 15 (93.3) >0.05
Norﬂoxacinc 107 (98.1) 78 (92.3) >0.05
TMP-SMX 107 (79.4) 78 (75.6) >0.05
Dual resistance 107 (1.9) 78 (5.1) >0.05
Multiresistance 107 (6.5) 78 (10.3) >0.05
Age >45 years
Ampicillin 112 (66.1) 133 (51.1) 0.026
Amoxicillin–clavulanic acid 112 (80.4) 133 (68.4) 0.049
Cefuroxime axetil 112 (81.3) 133 (64.7) 0.006
Fosfomycin 14 (100) 19 (100.0) >0.05
Nitrofurantoin 18 (100) 32 (84.4) >0.05
Norﬂoxacinc 112 (90.2) 133 (76.7) 0.009
TMP-SMX 112 (79.5) 133 (71.4) >0.05
Dual resistance 112 (5.4) 133 (12.8) >0.05
Multiresistance 112 (8.9) 133 (20.3) 0.022
ESBL, extended-spectrum b-lactamase; SD, standard deviation; TMP-SMX, trimethoprim–sulphamethoxazole.
aMissing data: age, n = 77; gender, n = 65; rural/urban, n = 10; missing data were equally distributed between solicited
and routine samples (data not shown).
bNumber and percentage of urinary samples with signiﬁcant bacterial growth. The total sum of microorganisms
exceeds 100%, because some samples contained more than one pathogen.
cComparison of susceptibility to norﬂoxacin between the two age groups: p 0.028 for solicited samples; p 0.007 for
routine samples.
TABLE 2. Susceptibility rates (%) and number tested (n) of
Escherichia coli urinary tract isolatesa stratiﬁed according to
antimicrobial exposure during the last 3 months
Antimicrobial treatment in the
last 3 months
p
Yes No
% n % n
Ampicillin 46.4 110 66.5 316 <0.001
Amoxycillin–clavulanic acid 61.8 110 81.6 316 <0.001
Cefuroxime axetil 60.9 110 78.5 316 <0.001
Fosfomycin 100.0 16 100.0 40 >0.05
Nitrofurantoin 79.2 24 98.2 55 0.009
Norﬂoxacin 70.9 110 94.6 316 <0.001
TMP-SMX 57.3 110 83.9 316 <0.001
TMP-SMX, trimethoprim–sulphamethoxazole.
aSolicited and routine samples combined.
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the solicited sample was obtained from a 35-year-old women
with an axillary abscess, whose father carried a community-
acquired MRSA isolate. MRSA infection or carriage was not
suspected in this patient before testing. Both MRSA isolates
were susceptible to trimethoprim–sulphamethoxazole, cipro-
ﬂoxacin, tetracycline, and clindamycin; in addition, the isolate
of the polytrauma patient was susceptible to gentamicin.
Discussion
Standard care for prevalent infections, such as uncomplicated
UTIs, respiratory tract infections, and skin infections, does
not require microbiological work-up [10–12]. If indicated,
the choice of empirical antimicrobial treatment is based on
epidemiological data for (local) antibiotic resistance preva-
lence. Active surveillance for antimicrobial susceptibility is
expensive, and is therefore often substituted for by passive
surveillance based on data from routine clinical microbiology
laboratories. By virtue of the standards of care, such passive
surveillance tends to over-represent complicated clinical situ-
ations, such as infectious episodes in patients with comorbid-
ity or recent antimicrobial exposure, or infections with signs
of invasiveness. All of these factors may be associated with
higher antimicrobial resistance prevalence. In order to cor-
rect for such potential bias, laboratory-based surveillance
data should be validated against active surveillance data [10].
Surveillance of antibiotic resistance in urinary tract isolates
The estimated annual incidence rate of lower UTI in our
population was 1.6 episodes per 100 population, which is
slightly above the rate of 1.3 episodes per 100 population
reported by a laboratory-based passive surveillance study
performed in the Calgary area between 2004 and 2005 [13].
The higher incidence observed in our study is probably a
consequence of soliciting samples from non-complicated
UTIs during the active surveillance study.
Signiﬁcant bacteriuria was observed in about two-thirds
(68.5%) of urinary samples, which is slightly lower than the
rate of 74.6% observed in the large international survey
TABLE 3. Socio-demographic, clinical and microbiological
characteristics of patients with skin infectionsa
Solicited
samples,
n = 84
Routine
samples,
n = 113 p
Demographic and clinical characteristics
Age (years), mean (SD) 37.5 (20.8) 50.3 (23.0) <0.001
Male gender, n (%) 36 (42.9) 58 (51.3) NS
Rural, n (%) 20 (23.8) 28 (24.8) NS
Type of infection
Abscess/folliculitis, n (%) 47 (56.0) 51 (45.1) >0.05
Wound infection, n (%) 22 (26.2) 27 (23.9) >0.05
Chronic ulcer, n (%) 3 (3.6) 17 (15.0) 0.016
Impetigo, n (%) 7 (8.3) 10 (8.8) >0.05
Antimicrobial treatment during
the last 3 months, n (%)
6 (7.1) 29 (25.7) 0.002
MRSA carriage known, n (%) 1 (1.2) 3 (2.7) >0.05
Long-term care, n (%) 3 (3.6) 6 (5.3) >0.05
Bacteriology
Culture-positive, n (%)b 54 (64.3) 73 (64.6) >0.05
Staphylococcus aureus 35 (64.8) 52 (71.2) >0.05
Streptococcus pyogenes 5 (9.3) 3 (4.1) >0.05
Coagulase-negative staphylococci 1 (1.9) 2 (2.7) >0.05
Other Gram-positive cocci 7 (13.0) 11 (15.1) >0.05
Enterobacteriaceae 8 (12.5) 9 (12.3) >0.05
Other Gram-negative rods 7 (14.8) 7 (9.6) >0.05
Anaerobes 1 (1.9) 1 (1.4) >0.05
MRSA, methicillin-resistant Staphylococcus aureus; NS, not signiﬁcant; SD, stan-
dard deviation.
aMissing data: age, n = 16; gender, n = 6; rural vs. urban, n = 8; missing data
were equally distributed between solicited and routine samples (data not
shown).
bNumber and percentage of samples with bacterial growth. The total sum of
microorganisms exceeds 100%, because some samples contained more than one
pathogen.
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FIG. 2. Susceptibility rates (%) of Staphylococcus aureus skin infection isolates in routine vs. solicited samples. The numbers of isolates tested
were 36 for solicited samples, except for ciproﬂoxacin and rifampicin with 34 isolates each, and 52 for routine samples. There were no signiﬁ-
cant differences between solicited and routine samples.
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ARESC [14]. As expected, E. coli was the most common uro-
pathogen [14,15]. However, the proportion of E. coli was sig-
niﬁcantly higher in solicited samples, probably because these
samples were from young, healthy women. Naber et al.
described a lower prevalence of E. coli in recurrent UTIs and
in UTIs in pregnant or young diabetic patients [14,15].
In this study, susceptibility rates for E. coli were signiﬁ-
cantly higher in clinical situations for which microbiological
work-up is not a standard (solicited samples) than in situa-
tions for which urine culture is recommended (routine sam-
ples). This difference was, however, mainly observed in
patients older than 45 years.
For trimethoprim–sulphamethoxazole, susceptibility rates
tended to be higher in solicited samples (79.2%) than in
routine samples (73.3%, p 0.16). It has been argued that tri-
methoprim–sulphamethoxazole should be maintained as a
valuable option for ﬁrst-line therapy of uncomplicated cysti-
tis, given the high clinical success rate (85%), even at a
resistance prevalence of 30% [16]. Therefore, trimetho-
prim–sulphamethoxazole remains a therapeutic option in
our region. However, trimethoprim–sulphamethoxazole sus-
ceptibility varies widely between different European coun-
tries, from 59.6% in Hungary to 87.7% in France [15].
Therefore, local active surveillance is important in order to
evaluate the appropriateness of this drug for empirical treat-
ment.
Susceptibility rates for norﬂoxacin were higher than those
for trimethoprim–sulphamethoxazole, and were signiﬁcantly
higher in solicited (93.5%) than in routine samples (82.3%,
p <0.001). Higher susceptibility rates for ciproﬂoxacin than
for trimethoprim–sulphamethoxazole are observed in all
European countries participating in the ARESC study [15].
However, rising trends in ﬂuoroquinolone resistance have
been shown over the past 7 years all over Europe [17], and
also for ambulatory E. coli isolates in Switzerland between
2004 and 2007 [18]. This correlates with increased consump-
tion of ﬂuoroquinolones in most European countries [19].
High resistance levels threaten the safety of empirical treat-
ment of invasive UTIs with a quinolone. Our study shows that
empirical use of quinolones in invasive UTIs may still be cor-
rect in patient populations at low risk of resistance, despite
high overall resistance levels. However, this information might
be missed if surveillance is based on passive surveillance only.
Susceptibility patterns for the b-lactam antibiotics amoxi-
cillin–clavulanic acid and cefuroxime axetil were comparable.
For both antibiotics, we observed signiﬁcantly higher suscep-
tibility rates in solicited than in routine samples. The suscep-
tibility rates of approximately 80% for amoxicillin–clavulanic
acid and for cefuroxime observed in this study compare well
with the average results from the ARESC study, although
susceptibility rates for these antibiotics vary widely between
different European countries [15].
Susceptibility rates for nitrofurantoin and fosfomycin were
generally high, in accordance with the overall situation in Europe
[15]. However, these drugs may be increasingly used in popula-
tions at risk for UTI not responding to standard treatment
because of rising resistance rates. As shown in our study, multi-
resistance is signiﬁcantly more prevalent in routine samples.
This prevalence study showed that ESBL-producing E. coli
isolates are still rare in our region (0.4% in solicited samples;
1.1% in routine samples; p 0.4). Across Europe, ESBL rates in
community-acquired UTIs vary between 0.9% in France in 2006
[20], 1.9% in Italy in 2003 [21], 5.2% in Spain in 2006 [22], and
20.2% in Turkey in 2007 [23]. We did not perform molecular
typing of our ESBL-producing isolates, but a previous Swiss
study showed a predominance of CTX-M [24], as has been
described for Europe in general [15]. Most of the ESBL carriers
identiﬁed in our study had at least one of the described risk
factors, such as older age [3,25–28], diabetes mellitus [3,27],
prostatic disease [29], recurrent UTI [3,27,29], previous antimi-
crobial use [28,29], residence in a long-term-care facility [28],
and recent hospital admission [26–28].
Surveillance of antibiotic resistance in skin and soft tissue
infections
As expected, S. aureus was the most prevalent microorganism
found in skin and soft tissue infections in our population. Nei-
ther the microbial spectrum nor S. aureus susceptibility rates
differed meaningfully between solicited and routine samples.
MRSA rates were low (2.1%), and did not differ signiﬁcantly
between routine and solicited samples. This was also shown
in another study conducted recently in Switzerland [30].
In conclusion, in the outpatient setting, susceptibility rates
for E. coli isolates differ by age and indication for urinary cul-
ture. Surveillance based on samples taken during standard care
(routine samples) may underestimate susceptibility rates for
uncomplicated infections, especially among the elderly. Reports
of resistance data should include age stratiﬁcation. However,
surveillance based on routine samples predicts susceptibility
rates of S. aureus from skin infections well. As this study applies
to UTIs and skin infections diagnosed in general practice,
extrapolation of the observed results to other settings, such as
inpatients or specialized outpatient clinics, may not be possible.
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